inpart Industry Call for Opportunities

Seeking Synthetic Methods for Chemo- and Site-selective Bioconjugation in Proteins



Asahi Kasei Pharma, a global pharmaceutical company, is seeking chemical **conjugation methods for N- or C-terminal specific protein modifications**. In addition, the team is also interested in synthetic methods for **chemo-selective and site-selective bioconjugation**, including intermediate-site selective (e.g. Lysine- specific) bioconjugation.

Approaches of Interest:

- Ideally, submissions should include **experimental data** with the name of the model protein, reaction site and/or residue, conversion rate, and selectivity
- Methods that produce **high protein yields** are of highest interest and scaling up for **GMP production** should be possible
- Stable bond formation in buffered conditions
- To improve selectivity and conversion, the **method of traceless affinity compound** is acceptable

Out of Scope:

- Uncontrolled reactions at multiple sites are out of scope

Developmental Stages of Interest:

- Opportunities from basic research phase to Phase III are within scope, provided there is quantitative data using more than one model protein to confirm conversion rate, selectivity, and isolated yield

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Asahi Kasei Pharma has high interest biopharma technologies and is also open to hearing from CROs and CMOs. Additionally, novel research proposals are of interest and can be outlined using this submission form. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include technology licensing, project funding, and research collaborations.

Opportunities sought

- Technologies
- Academics and expertise
- Research projects
- Spinout companies
- Biotech assets
- Centres of excellence

Submissions

Please submit relevant, non-confidential opportunities to **Karla Schramm** at **kschramm@usf.edu**

Deadline: **9th June 2025 - 10:59 pm GMT**

Have any questions?
Contact **Karla Schramm** at **kschramm@usf.edu**

AsahiKASEI
ASAHI KASEI PHARMA

Asahi Kasei Pharma is focused on the discovery and development of new medicines that address unmet medical needs using proven drug discovery techniques and leading-edge technologies.